Alkermes (ALKS) Income from Discontinued Operations (2023 - 2024)
Alkermes (ALKS) posted quarterly Income from Discontinued Operations of 354000.0 for Q4 2024, down 94.88% year-over-year from 6914000.0 in Q1 2024, and up 628.36% quarter-over-quarter from 67000.0 in Q3 2024.
Alkermes (ALKS) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Alkermes (ALKS) has reported Income from Discontinued Operations for 2 consecutive years, with 354000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Income from Discontinued Operations fell 94.88% year-over-year to 354000.0; the TTM figure through Dec 2024 stood at 722000.0 (changed N/A YoY), while the FY2024 annual figure was 722000.0, up 48.54% from the prior year.
- Income from Discontinued Operations grew to 354000.0 in Q4 2024 per ALKS's latest filing, from 67000.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 6914000.0 in Q4 2023 and bottomed at 1550000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 354,000.00 |
| Sep 30, 2024 | -67,000.00 |
| Jun 30, 2024 | -613,000.00 |
| Mar 31, 2024 | -396,000.00 |
| Dec 31, 2023 | 6.91 Mn |
| Sep 30, 2023 | -1.55 Mn |
| Jun 30, 2023 | -40,000.00 |